Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker BFRI
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Master Fund L.P. | 15.92M | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Aharon Gil | 15.92M | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Salamon Steven A J | 15.92M | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Advisors, Inc. | 15.92M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Master Fund L.P. | 16.80M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Aharon Gil | 16.80M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Salamon Steven A J | 16.80M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Advisors, Inc. | 16.80M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 11, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Master Fund L.P. | 16.19M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 11, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Aharon Gil | 16.19M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 11, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Salamon Steven A J | 16.19M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 11, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Advisors, Inc. | 16.19M | 9.9% | SCHEDULE 13G/A ↗ |
| Jan 28, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | AIGH Capital Management LLC | 915,210 | 7.9% | SCHEDULE 13G/A ↗ |
| Jan 28, 2026 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Orin Hirschman | 915,210 | 7.9% | SCHEDULE 13G/A ↗ |
| Nov 12, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Master Fund L.P. | 16.78M | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 12, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Aharon Gil | 16.78M | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 12, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Salamon Steven A J | 16.78M | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 12, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Advisors, Inc. | 16.78M | 9.9% | SCHEDULE 13G/A ↗ |
| Sep 19, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Maria del Pilar de la Huerta Martinez | 2.49M | 19.5% | SCHEDULE 13D/A ↗ |
| Sep 19, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Hansjoerg Plaggemars | 2.55M | 20.0% | SCHEDULE 13D/A ↗ |
| Sep 19, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Alexander Link | 2.55M | 20.0% | SCHEDULE 13D/A ↗ |
| Sep 19, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Wilhelm Konrad Thomas Zours | 2.55M | 20.0% | SCHEDULE 13D/A ↗ |
| Sep 19, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Delphi Unternehmensberatung Aktiengesellschaft | 2.55M | 20.0% | SCHEDULE 13D/A ↗ |
| Sep 19, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | VV Beteiligungen Aktiengesellschaft | 2.55M | 20.0% | SCHEDULE 13D/A ↗ |
| Sep 19, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Deutsche Balaton Aktiengesellschaft | 2.55M | 20.0% | SCHEDULE 13D/A ↗ |
| Sep 19, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Biofrontera AG | 2.49M | 19.5% | SCHEDULE 13D/A ↗ |
| Aug 11, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Master Fund L.P. | 14.43M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 11, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Aharon Gil | 14.43M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 11, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Salamon Steven A J | 14.43M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 11, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Advisors, Inc. | 14.43M | 9.9% | SCHEDULE 13G/A ↗ |
| Jul 25, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Pilar de la Huerta Martinez | 400,000 | 4.2% | SCHEDULE 13D/A ↗ |
| Jul 25, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Hansjoerg Plaggemars | 458,884 | 4.9% | SCHEDULE 13D/A ↗ |
| Jul 25, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Alexander Link | 458,884 | 4.9% | SCHEDULE 13D/A ↗ |
| Jul 25, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Wilhelm Konrad Thomas Zours | 458,884 | 4.9% | SCHEDULE 13D/A ↗ |
| Jul 25, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Delphi Unternehmensberatung Aktiengesellschaft | 458,884 | 4.9% | SCHEDULE 13D/A ↗ |
| Jul 25, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | VV Beteiligungen Aktiengesellschaft | 458,884 | 4.9% | SCHEDULE 13D/A ↗ |
| Jul 25, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Deutsche Balaton Aktiengesellschaft | 458,884 | 4.9% | SCHEDULE 13D/A ↗ |
| Jul 25, 2025 | SCHEDULE 13D/A (amended) | BFRI Biofrontera Inc. | Biofrontera AG | 400,000 | 4.2% | SCHEDULE 13D/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Laurence W. Lytton | 306,700 | 3.5% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Master Fund L.P. | 9.89M | 9.9% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Aharon Gil | 9.89M | 9.9% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Salamon Steven A J | 9.89M | 9.9% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Advisors, Inc. | 9.89M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Master Fund L.P. | 9.96M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Aharon Gil | 9.96M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Salamon Steven A J | 9.96M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Rosalind Advisors, Inc. | 9.96M | 9.9% | SCHEDULE 13G/A ↗ |
| Jan 29, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | AIGH Capital Management LLC | 884,563 | 9.9% | SCHEDULE 13G/A ↗ |
| Jan 29, 2025 | SCHEDULE 13G/A (amended) | BFRI Biofrontera Inc. | Orin Hirschman | 884,563 | 9.9% | SCHEDULE 13G/A ↗ |
49 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:54 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances